Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
1.
Curr Hypertens Rev ; 18(1): 78-84, 2022.
Article in English | MEDLINE | ID: covidwho-1902800

ABSTRACT

BACKGROUND: Hypertension is a leading risk factor for morbidity and mortality around the world. Preventing this health problem is considered an important priority. The aim of this study was to investigate the predictive factors for care and control of hypertension (CCH) according to the health belief model (HBM), in patients with hypertension during the COVID-19 epidemic in Sirjan, Iran. METHODS: In this cross-sectional study, participants were chosen by simple random sampling. Data were collected by a valid and reliable researcher-made questionnaire from 200 patients with high blood pressure aged 30-60 years. Data were analyzed by SPSS21 and analysis based on descriptive statistics, Pearson correlation coefficients, and linear regression was conducted. RESULTS: The results of Pearson correlation coefficients showed that there was a significant correlation among almost all constructs of the Health Belief Model (HBM), but the strongest correlations were between self-efficacy and perceived susceptibility (r = 0.940, P ≤ 0.001), and between perceived barriers with perceived benefits (r = -0.615, P ≤ 0.001). According to linear regression, perceived barriers (ß = -0.291), cues to action (ß = -0.590), and knowledge (ß = 0.973) predicted more than 26% of CCH variability. Knowledge had a stronger role than other variables. CONCLUSION: The results of this study show that the constructs of the Health Belief Model can predict CCH in hypertensive patients. This model can be used as a tool for designing and implementing educational interventions to increase CCH among hypertensive patients.


Subject(s)
COVID-19 , Hypertension , COVID-19/epidemiology , Cross-Sectional Studies , Health Belief Model , Health Knowledge, Attitudes, Practice , Humans , Hypertension/diagnosis , Hypertension/epidemiology , Hypertension/therapy , Iran/epidemiology
2.
Int J Biol Macromol ; 188: 740-750, 2021 Oct 01.
Article in English | MEDLINE | ID: covidwho-1356252

ABSTRACT

The world has been suffering from COVID-19 disease for more than a year, and it still has a high mortality rate. In addition to the need to minimize transmission of the virus through non-pharmacological measures such as the use of masks and social distance, many efforts are being made to develop a variety of vaccines to prevent the disease worldwide. So far, several vaccines have reached the final stages of safety and efficacy in various phases of clinical trials, and some, such as Moderna/NIAID and BioNTech/Pfizer, have reported very high safety and protection. The important point is that comparing different vaccines is not easy because there is no set standard for measuring neutralization. In this study, we have reviewed the common platforms of COVID-19 vaccines and tried to present the latest reports on the effectiveness of these vaccines.


Subject(s)
COVID-19 Vaccines/immunology , COVID-19/prevention & control , Animals , COVID-19/immunology , COVID-19 Vaccines/chemistry , Humans , Immunogenicity, Vaccine , Protein Subunits/immunology , SARS-CoV-2/physiology , Vaccines, DNA/immunology , Vaccines, Synthetic/immunology
SELECTION OF CITATIONS
SEARCH DETAIL